FDA Grants Bevacizumab Full Approval for Glioblastoma

December 5, 2017 – The FDA has granted bevacizumab a full approval for the treatment of adult patients with glioblastoma that progressed following prior therapy, according to Genentech, the manufacturer of the VEGF inhibitor. Bevacizumab previously received an accelerated approval in this setting. The conversion to a full approval is based on findings from the phase III EORTC 26101 study, in which adding bevacizumab to lomustine chemotherapy reduced the risk of … (leggi tutto)